NCT06853743View on ClinicalTrials.gov

The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in Huntington's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2029

Conditions
Huntington Disease
Interventions
DIETARY_SUPPLEMENT

Nicotinamide Riboside (NR)

Nicotinamide riboside, 2 capsules of 500mg taken twice daily for 2 years

DIETARY_SUPPLEMENT

Placebo

Placebo, 2 capsules twice daily for 2 years

Trial Locations (1)

0372

RECRUITING

Oslo University Hospital, Oslo

Sponsors

Collaborators (1)

Elysium Health
All Listed Sponsors
collaborator

Haukeland University Hospital

OTHER

collaborator

South-Eastern Norway Regional Health Authority

OTHER

collaborator

Klinbeforsk

OTHER

collaborator

The Dam Foundation

OTHER

collaborator

Elysium Health

INDUSTRY

collaborator

NKS Olaviken Gerontopsychiatric Hospital

OTHER

lead

Oslo University Hospital

OTHER

NCT06853743 - The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in Huntington's Disease | Biotech Hunter | Biotech Hunter